Will MannKind Inhale Novo Nordisk's Profits?

MannKind is developing a revolutionary new insulin called Afrezza, which could compete directly with Novo Nordisk's  NovaLog and Eli Lilly's Humalog. Afrezza is inhalable and rapid-acting, which could change the way diabetes is treated.

The market opportunity for diabetes care is massive, but there are a few things investors should know about MannKind before moving forward. Motley Fool Rule Breakers analyst Simon Erickson and analyst Max Macaluso look at some of the challenges that face MannKind, as well as keys for the company to succeed.

The Motley Fool's top stock for 2014
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!


The article Will MannKind Inhale Novo Nordisk's Profits? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. Simon Erickson owns shares of Novo Nordisk. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story